We develop solutions to complex diseases

Clinical development

Hyperion Therapeutics, Inc. is developing DiaPep277, a first-in-class immunotherapy for the potential treatment of new onset Type 1 diabetes. The company is also developing glycerol phenylbutyrate for the potential treatment of hepatic encephalopathy (HE) and planning to initiate phase III clinical trials in HE at the end of 2014 or beginning of 2015.